ibogaine (MC-808)
/ Mindcure
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 27, 2021
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
(PRNewswire)
- "Mind Cure Health...announce it has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. During this stage, the Company will be assessing the quality of the synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing."
Commercial • Alzheimer's Disease • CNS Disorders • Pain • Parkinson's Disease
July 26, 2021
"$MCURF MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research https://t.co/LebTfpn9o9"
(@otcdynamics)
Clinical
July 13, 2021
MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound
(PRNewswire)
- "Mind Cure Health...announces the filing of provisional patent applications with the United States Patent and Trademark Office (USPTO) for innovative processes for synthesizing ibogaine....The Company has filed patent applications for two chemical synthesis routes, both of which successfully produced ibogaine."
Patent • Alzheimer's Disease • CNS Disorders • Pain • Parkinson's Disease
June 02, 2021
"$MCURF MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research https://t.co/Xept66rGNZ"
(@otcdynamics)
Clinical
March 04, 2021
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
(PRNewswire)
- "Mind Cure Health...is pleased to announce that the Company's bioinformatics platform, PsyCollage, has identified opportunities for ibogaine to support neuroregenerative pathways that the Company believes could be pivotal in treating neuropathic pain and brain trauma...MINDCURE is synthesizing ibogaine, as announced in a news release dated March 3, 2021, to be used in the Company's preclinical and clinical trials."
Clinical • Pain
1 to 5
Of
5
Go to page
1